A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Part of paid clinical trials in Denver, Colorado.

Sponsor
IDEAYA Biosciences
Study ID
NCT07503808
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IDE034 — DRUG
    IDE034

Study Details

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Key Dates

First listed
Mar 31, 2026
Start date
Feb 24, 2026
Status verified
Mar 2026
Primary completion
Jul 30, 2027
Completion
Jul 30, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1:IDE034 Dose Escalation
    IDE034 Dose Escalation Successive cohorts of participants will be treated with increasing doses of IDE034 until the maximum tolerated dose or the recommended dose for expansion is determined
  • Experimental: Part 2: IDE034 Dose Expansion
    IDE034 Dose Expansion To further assess the safety, tolerability, and preliminary antitumor activity at one or more dose levels of IDE034 selected from dose escalation

Primary Outcome Measure

Safety and tolerability of IDE034 in Part 1 dose escalation [ Time Frame: 21 days following the first dose of IDE034 ]

Central Contacts

Locations (15)

FacilityCityStateZIPSite coordinators
Sarah Cannon Research Institute at HealthONEDenverColorado80218
Gerald Falchook
[email protected]
(615) 329-7274
Florida Cancer SpecialistsSarasotaFlorida34232
Manish Patel
[email protected]
(941) 377-9993
Karmanos Cancer InstituteDetroitMichigan48201
START New York Long Island, LLCLake SuccessNew York11042
Geraldine O'Sullivan Coyne
[email protected]
363-207-5160
SCRI Oncology PartnersNashvilleTennessee37203
Deepak Bhamidipati
[email protected]
615-329-7640
NEXT Texas LLC - AustinAustinTexas78758
Sheena Sahota
[email protected]
737-610-5200
START Dallas Fort Worth, LLCFort WorthTexas76104
Henry Xiong
[email protected]
682-350-3010
MD AndersonHoustonTexas77030
Timothy Yap
[email protected]
1-866-918-1601
NEXT Texas LLC - HoustonHoustonTexas77054
Jennifer Segar
[email protected]
832-384-7900
NEXT Texas LLC - DallasIrvingTexas75039
Michael Song
[email protected]
972-893-8800
NEXT Texas LLC - San AntonioSan AntonioTexas78229
Dr. Sommerhalder
[email protected]
210-580-9500
START San Antonio, LLCSan AntonioTexas78229
Kyriakos Papadopoulos
[email protected]
210-593-5250
START Mountain Region, LLCWest Valley CityUtah84119
Jose Pacheco
[email protected]
801-907-4750
NEXT Texas LLC - VirginiaFairfaxVirginia22031
Alexander Spira
[email protected]
703-783-4510
Medical Oncology AssociatesSpokaneWashington99208
Arvind Chaudhry
[email protected]
5094622273

Find similar trials in Denver, CO

By condition
Colorectal cancerHead and neck cancerLung cancerBreast cancer
By specialty
OncologyGI oncologyENTLung oncologyLung diseaseBreast oncologyWomen's health
By research site
Sarah Cannon Research Institute at HealthONE· Denver, COFlorida Cancer Specialists· Sarasota, FLKarmanos Cancer Institute· Detroit, MISTART New York Long Island, LLC· Lake Success, NYSCRI Oncology Partners· Nashville, TNNEXT Texas LLC - Austin· Austin, TX

Related Studies